Company news

Compugen Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Compugen Reports Second Quarter 2024 Results

August 5, 2024

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

July 28, 2024

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

July 22, 2024

Compugen to Present at Upcoming Antibody Industrial Symposium

June 16, 2024

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

May 29, 2024

Compugen Reports First Quarter 2024 Results

May 19, 2024

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024

Compugen Appoints David Silberman as Chief Financial Officer

May 14, 2024

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

May 5, 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

April 24, 2024

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

April 9, 2024

Compugen to Participate in Two Upcoming Investor Conferences

April 2, 2024

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

March 10, 2024

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

March 5, 2024

Compugen Reports Fourth Quarter and Full Year 2023 Results

March 4, 2024

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

February 25, 2024

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

February 19, 2024

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

February 14, 2024

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

January 7, 2024

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

January 7, 2024

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

December 18, 2023

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

December 18, 2023

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

December 18, 2023

Compugen Reports Third Quarter 2023 Results

November 6, 2023

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

November 5, 2023

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

November 2, 2023

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer

October 30, 2023

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023

October 23, 2023

Compugen to Present at Single Cell Genomics 2023 Meeting

October 2, 2023

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

October 1, 2023

Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

September 26, 2023

Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 30, 2023

Compugen Reports Second Quarter 2023 Results

August 6, 2023

Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023

July 23, 2023

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

July 16, 2023

Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

June 21, 2023

Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer

June 4, 2023

Compugen Reports First Quarter 2023 Results

May 14, 2023

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

May 10, 2023

Compugen to Present at the JMP Securities Life Sciences Conference

May 8, 2023

Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023

April 30, 2023

Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023

April 26, 2023

Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting

April 25, 2023

Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023

March 14, 2023

Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023

Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study

March 5, 2023

Compugen Reports Fourth Quarter and Full Year 2022 Results

February 26, 2023

Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

February 13, 2023

Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

February 12, 2023

Compugen to Present at the SVB Securities Global Biopharma Conference

February 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.